Excitement was in the air during Westfield Public School’s STEM Week, Oct. 20 to 24, when a lot of special activities were ...

GV- and Arch-backed Pelage Pharma is developing a first-of-its-kind topical stem-cell therapy that could redefine the $10B ...

What should you pack to optimise your wellbeing on your next trip? We talk to the experts to get their tips and discover the ...

Elevated carbohydrate antigen 19-9 (CA19-9) levels post resection indicate aggressive tumor biology and higher ... which were all Grade 1 or 2. Only one case of Grade 3 gastritis occurred. No immune ...

AlphaTON Capital Corp ( Nasdaq: ATON) and its wholly owned oncology-focused subsidiary Tarus Therapeutics, LLC, operating as Cyncado Therapeutics, today announced that a new poster is live at the AACR ...

Among 16 patients with this difficult-to-treat tumor "with few treatment options," the confirmed overall response rate (ORR) ...

Phase 2 clinical trial underway with first patient dosed in October to support a clear path to Phase 3 based on previous ...

In an economy of commodified morality, I have the privilege of majoring in political science and media studies with a minor ...

Bristol Myers BMY recently announced that it will acquire privately held biotechnology company Orbital Therapeutics for $1.5 billion in cash. The acquisition will add OTX-201, an investigational ...

Zenocutuzumab (Bizengri), a bispecific antibody that targets human epidermal growth factor receptor 2 (HER2) and HER3, led to responses in more than a third of patients with neuregulin 1 ...

The combination of pembrolizumab (Keytruda) and lenvatinib (Lenvima) elicited promising progression-free survival (PFS) outcomes in patients with uveal melanoma who were both HLA-A*02:01–negative and ...